COMMUNIQUÉS West-GlobeNewswire

Orchestra BioMed Reports First Quarter 2026 Financial Results and Highlights Recent Business Updates
12/05/2026
Orchestra BioMed targeting enrollment completion of BACKBEAT Global Pivotal Trial (“BACKBEAT Trial”) by the end of Q3 2026 Medtronic (NYSE: MDT) and Orchestra BioMed intend to pursue late-breaking clinical trial [...]
InnovAge Appoints Jennifer Browne as President and Chief Operating Officer
12/05/2026
DENVER, May 12, 2026 (GLOBE NEWSWIRE) -- InnovAge Holding Corp. (“InnovAge” or the “Company”) (Nasdaq: INNV), an industry leader in providing comprehensive healthcare programs to frail, predominantly dual-eligible [...]
Eton Pharmaceuticals to Participate in Upcoming Investor Conferences
12/05/2026
DEER PARK, Ill., May 12, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare [...]
Anaptys Announces First Quarter 2026 Financial Results and Provides Business Update
12/05/2026
Completed spin-off of First Tracks Biotherapeutics, Inc., its former biopharma operations business Now exclusively manages the financial collaborations for Jemperli with GSK and imsidolimab with Vanda Announced [...]
COSCIENS Biopharma Inc. Reports Q1 2026 Results
12/05/2026
TORONTO, ONTARIO, May 12, 2026 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (TSX: CSCI) (OTCQB: CSCIF) (“ COSCIENS ” or the “ Company ”) today reported its financial and operating results for the first quarter ended [...]
Palisade Bio Reports First Quarter 2026 Financial Results and Highlights Continued Clinical Progress of PALI-2108
12/05/2026
Advancing potentially best-in-class once-daily oral, locally-activated PDE4 inhibitor prodrug for treatment of IBD Phase 2 Ulcerative Colitis (UC) trial expected to commence 3Q 2026 Strong balance sheet expected to [...]
Nurix Therapeutics Announces Bexobrutideg Oral Presentation at the 2026 European Hematology Association Congress
12/05/2026
BRISBANE, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein [...]
Nyxoah Reports First Quarter 2026 Financial and Operating Results
12/05/2026
REGULATED INFORMATION Nyxoah Reports First Quarter 2026 Financial and Operating Results Strong Genio launch in the U.S. drove 25% sequential quarterly U.S. revenue growth Continued clarity around HGNS and Genio [...]
Alignment Healthcare Strengthens Leadership Team to Support Long-Term Growth and Shareholder Value Creation
12/05/2026
Founder and CEO John Kao Assumes Additional Role as Chairman of the Board ORANGE, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- Alignment Healthcare, Inc. (NASDAQ: ALHC) today announced leadership updates that further [...]
Lifecore Biomedical to Participate at CDMO Live Europe
12/05/2026
CHASKA, Minn., May 12, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR ) (“Lifecore”), a fully integrated injectables contract development and manufacturing organization (“CDMO”), today announced that [...]
Rezolute Reports Third Quarter Fiscal 2026 Financial Results and Provides Business Update
12/05/2026
REDWOOD CITY, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage rare disease company focused on treating hypoglycemia caused by all forms of [...]
Neumora Therapeutics to Participate in 2026 RBC Capital Markets Global Healthcare Conference
12/05/2026
WATERTOWN, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of programs that target novel mechanisms [...]
Fractyl Health Reports First Quarter 2026 Financial Results and Business Updates
12/05/2026
Next anticipated Revita ® clinical data readouts are 1-year data from the REVEAL-1 Cohort in Q2 2026 and 1-year randomized data from the REMAIN-1 Midpoint Cohort in Q3 2026 Early Q4 2026 timing for topline 6-month [...]
Eupraxia Pharmaceuticals Reports First Quarter 2026 Financial Results
12/05/2026
Robust response in highest dose cohort after 36 weeks following a single treatment of EP-104GI Completion of a $63.2 million public offering to enable clinical trials of EP-104GI in additional indications Well- [...]
Sana Biotechnology Presents Preclinical Data for In Vivo CAR T Cell Therapy SG293 Surrogate Demonstrating Cell-Specific Delivery, Potent CAR T Cell Generation, and Deep B Cell Depletion in NHPs
12/05/2026
Data presented at the American Society of Gene & Cell Therapy (ASGCT) 2026 Annual Meeting SEATTLE, May 12, 2026 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible [...]
BBOT Reports First Quarter 2026 Financial Results and Update on Corporate Progress
12/05/2026
Announced encouraging preliminary safety and efficacy data across all three RAS-pathway inhibitor programs Announced publication in Cancer Discovery highlighting preclinical data demonstrating BBO-11818 is a potent and [...]
Bolt Biotherapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
12/05/2026
First-in-class immune-stimulating antibody conjugate BDC-4182 Phase 1/2 study ongoing, initial clinical data expected in 3Q 2026 Cash balance of $23.9 million as of March 31, 2026 anticipated to fund operations into [...]
Solid Biosciences Reports First Quarter 2026 Financial Results and Provides Business Updates
12/05/2026
- Duchenne (SGT-003): First participant dosed in the Phase 3 IMPACT DUCHENNE clinical trial, receipt of positive opinion on the Company’s Pediatric Investigation Plan from the European Medicines Agency and Orphan drug [...]
DBV Technologies participera à la 4e édition de la conférence annuelle BioConnect Investor organisée par H.C. Wainwright au Nasdaq
12/05/2026
Châtillon, France, le 12 mai (22 :30 CEST) 2026 DBV Technologies participera à la 4e édition de la conférence annuelle BioConnect Investor organisée par H.C. Wainwright au Nasdaq DBV Technologies (Euronext : DBV – ISIN [...]

Pages